Jaguar Health Q1 Revenue +816% to $20.27M; Net Loss $7.02M
Jaguar Health reported a significant increase in Q1 2026 total net revenue, up 816% year-over-year to $20.27 million, primarily driven by a U.S. licensing agreement for Mytesi and Canalevia-CA1. The company also saw a substantial improvement in income from operations, moving from a loss to a profit, and a reduced net loss. This strategic shift allows Jaguar to focus on crofelemer development for rare-disease intestinal failure indications, despite a decrease in prescription product revenue.
Key Highlights
- Total net revenue increased 816% to $20.27 million in Q1 2026 from $2.21 million in Q1 2025.
- License and grant revenue surged to $19.07 million in Q1 2026 from $43,000 in Q1 2025.
- Product revenue decreased 45% to $1.20 million in Q1 2026 from $2.17 million in Q1 2025.
- Income from operations improved by $19.6 million, reaching $10.18 million in Q1 2026 from a $9.42 million loss in Q1 2025.
- Net loss attributable to common stockholders decreased 33% to $7.02 million in Q1 2026 from $10.46 million in Q1 2025.
- Sales and Marketing expense decreased by $1.6 million to $0.9 million in Q1 2026.
- R&D expense increased by $0.2 million to $3.9 million in Q1 2026.
- Non-GAAP Recurring EBITDA was a net loss of $5.06 million in Q1 2026, an improvement from a $9.74 million loss in Q1 2025.
Price Impact
More from JAGX
Jaguar Health Completes Series O Preferred Stock Conversion; 4.86M Common Shares Outstanding
Jaguar Health Converts Series O Preferred Stock to Common
Jaguar Health Explores Strategic Alternatives for Rare Disease Program